BioSpace News Archive

Bristol-Myers Squibb Company (NYSE: BMY) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lisocabtagene maraleucel (liso-cel)

Geron Corporation (Nasdaq: GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of imetelstat in patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF.

Arcutis Biotherapeutics, Inc., a privately held late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced top line results for a Phase 2 proof-of-concept study evaluating ARQ-151 as a potential topical treatment for atopic dermatitis (AD).

Achievement marks 15th consecutive year of meeting early certification requirements

Padcev represents a new type of therapy for patients with advanced urothelial cancer whose disease has progressed on chemotherapy and immunotherapy.

The Company has filed the New Drug Application (NDA) for lurbinectedin, in monotherapy, for the treatment of relapsed Small Cell Lung Cancer (SCLC), under the “accelerated approval” regulations.

Centene Corporation announced the extension of the expiration date of the offers to exchange notes issued by WellCare Health Plans, Inc.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that, following a strategic portfolio decision by Novartis not to exercise its option, Akcea has retained rights to develop and commercialize AKCEA-APOCIII-LRx.

Technavio has announced its latest market research report titled global conjugate vaccines market 2020-2024

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer